This trial is evaluating whether CELLECTRA®2000 EP Device supplied by Geneos Therapeutics will improve 4 primary outcomes and 8 secondary outcomes in patients with Glioblastoma. Measurement will happen over the course of Week 10 post-vaccination.
This trial requires 12 total participants across 1 different treatment group
This trial involves a single treatment. CELLECTRA®2000 EP Device Supplied By Geneos Therapeutics is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"The cause of glioblastoma is unknown, but there is compelling evidence that many of the genes associated with the development of glioblastoma are overexpressed in normal glial cells. It is also suspected that many of the genes associated with cancer are overexpressed in glioblastoma to enable the development of a tumor. Genetic changes can lead to the production of an aberrant protein, which may be responsible for the development of glioblastoma. The exact role of smoking, alcohol, cannabis, and other drugs in the causation of glioblastoma remains uncertain, but there is evidence to suggest that such agents may trigger genomic changes that have important implications for the development of the tumor." - Anonymous Online Contributor
"This is a cancer that forms inside the brain in individuals over the age of 50. It can be malignant, meaning it can multiply or invade the blood vessels within the brain, and non-malignant, meaning it has low or limited capabilities to invade other areas of the brain.\n" - Anonymous Online Contributor
"About 15,000 new cases of glioblastoma are expected annually (12,000 cases will be fatal). The projected survival, survival adjusted relative to 1,500 patient deaths, and projected 5 year survival for survivors of glioblastoma are described. These data will be important for assessing future needs and for communicating with patients with this extremely rare malignancy." - Anonymous Online Contributor
"For patients matched on age, no prognostic factors or genotype were predictive of remission. Patients with glioblastoma should be evaluated for the presence of epidermidine-plasma-proteinase activity; such patients may benefit from clinical trial treatments, including bevacizumab. However, the role of current conventional treatments deserves further investigation." - Anonymous Online Contributor
"The standard of care and treatment for glioblastoma is highly variable among the world's leading centers. The identification of these variations and the determination of their impact on survival would be a critical step in enhancing survival rates. A significant proportion of patients with low/intermediate/high survival rates have a higher mortality due to poor compliance with or adherence to treatment guidelines." - Anonymous Online Contributor
"The early signs of glioblastoma are subtle with no visible enlargement of the tumor. These early signs include dizziness, visual disturbances, headache, abnormal vision, and loss of sensation. A headache history and neurologic exam (including peripheral neuropathy) should be obtained routinely in adult glioblastoma patients." - Anonymous Online Contributor
"In a recent study, findings, we showed that the use of ep-CTX and cellectra®2000 ep device for long-term palliative treatment did not produce a significant therapeutic benefit for patients with recurrent/progressive glioblastoma. The safety profile of this regimen observed suggests that patients must be carefully monitored for potential side effects during treatment with the ep-CTX and cellectra®2000." - Anonymous Online Contributor
"Cellectra®2000 ep device supplied by Geneos was an effective treatment of the patients at the study site. Treatment with the Cellectra®2000 epid device was well tolerated." - Anonymous Online Contributor
"A genetic abnormality in GBM may be involved in the pathogenesis of the neoplasm. This knowledge may lead to the development of improved glioblastoma approaches, potentially by suppressing the proliferative and/or invasive potential of glioblastoma cells, and/or by targeting mutated receptors." - Anonymous Online Contributor
"TACE (transarterial chemoembolization), an interventional radiologic treatment, is now being routinely employed when conventional therapies fail or when patients are not available for conventional multimodal treatment. The technique involves injecting a radiochemically generated mixture of radioactive microspheres into the arteries supplying the tumor, causing cell death by necrosis, or cell death by apoptosis, depending on the type of cell and the cancer. When the cells are already dead they will not proliferate to form a tumor. This contrasts with most other treatments that do not involve the injection of radioactive materials - thereby affecting not only tumors, but also nearby healthy tissues." - Anonymous Online Contributor
"Data from a recent study showed that patients with glioblastoma had greater improvement in overall QoL and physical functioning with the Cellectra 2000 device. Additional investigation is required to test causal assumptions." - Anonymous Online Contributor
"At this point we've only collected information from people with glioblastomas. The average age of diagnosis of glioblastoma is much higher than the one from the general population. The average age at diagnosis of pediatric patients with glioblastomas is 9.6 months, while in the United States the average age for pediatric patients with glioblastomas is 4.5 to 5.9 months. Therefore, this may indicate that pediatric patients are experiencing the disease later, or that there is a predisposing factor in younger children with the disease. Also, this is only a report from Iran where there is a high rate of children with the disease." - Anonymous Online Contributor